• Explore /
  • Poster
  • / ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.

ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.

Abstract Poster

Authors

null

Jingnan Shen

Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

Jingnan Shen , Wei Guo , Jin Wang , Xianbiao Xie , Lu Xie , Jie Xu , Chen Jing , Jianhua Lin , Xianan Li , Yong Zhou , Guowen Wang , Xiaojing Zhang , Yao Weitao , Yang Dong , Zhaoming Ye , Li Wang , Yanyan Zeng , Yongyong Wu , Xiugao Yang , Yanfeng Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Bone Tumors

Clinical Trial Registration Number

NCT04886765

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11530)

DOI

10.1200/JCO.2023.41.16_suppl.11530

Abstract #

11530

Poster Bd #

464

Abstract Disclosures

Similar Posters

First Author: Xue Bai

First Author: Yuanyuan Zhao

First Author: Samuel J Klempner

First Author: Anthony W. Tolcher